Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus BETA HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus BETA HC.
ACLOVATE vs BETA-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
None Documented
None Documented
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid